HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $6 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on SAB Biotherapeutics (NASDAQ:SABS) and maintained a price target of $6.
May 21, 2024 | 10:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on SAB Biotherapeutics and maintained a price target of $6, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $6 price target by a reputable analyst firm like HC Wainwright & Co. is likely to boost investor confidence in SAB Biotherapeutics, potentially leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100